Scott Rocklage has been a significant contributor in the healthcare industry for over three decades. In addition to bringing several medications to drug trial, he helped lead the way towards FDA approval of Cubicin, Teslascan and Omniscan. He is also said to be an inventor and holds several US patents.
Academically, Scott Rocklage holds a B.S. degree and PhD degree in Chemistry. Since 2003, Dr. Rocklage has been with the company 5AM Ventures and a managing partner starting in 2004.
Dr. Rocklage describes his day as atypical, and his role as developmental in that he meets with scientists who are by nature entrepreneurial and want to shape a medical idea to fit the marketplace. He describes the company name, 5AM Ventures, to depict the dynamic of research and ideas being addressed at their beginning phase, or dawn. One such example is in the area of Expansion Therapeutics.
The company, 5AM Ventures, along with other industry participants, have contributed up to $55 million towards research in what are known as RNA-triggered conditions or illnesses. One such example is DM1 also called Myotonic Dystrophy type I. This is believed to be the primary cause of adult muscular dystrophy. The main symptom is when DNA converts to RNA molecules, and the levels become too high or numerous inside cells that they become toxic. At this point body systems such as the heart and gastrointestinal system show signs of breaking down.
At present there is no permanent cure for this, but the laboratory of Matthew Disney has developed what are termed small molecule medications. These lessen or minimize the amount of damage excessive RNA build-up can ultimately lead to. Dr. Rocklage and others involved with this area of research and Expansion Therapeutics are hopeful that real progress can continue to be made and realized in the months ahead.
Dr. Rocklage has previously served as CEO and chair with medical companies to include Novira, which was acquired by Johnson and Johnson, Salutar and Catalytica.
Connect with Dr. Scott Rocklage on LinkedIn.